Evidence map›Paper›PMID 34410978›Full record

ArticleIn vivo (Athens, Greece)

Albumin-to-Alkaline Phosphatase Ratio as a Novel Prognostic Marker of Nivolumab Monotherapy for Previously Treated Metastatic Renal Cell Carcinoma.

Maki Yoshino, Hiroki Ishihara, Yudai Ishiyama, Hidekazu Tachibana, Daisuke Toki, Kaori Yamashita, Hirohito Kobayashi, Hironori Fukuda, Kazuhiko Yoshida, Toshio Takagi and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in In vivo (Athens, Greece). The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Maki YoshinoDepartment of Urology, Tokyo Women's Medical University Medical Center East, Arakawa, Japan.
Hiroki IshiharaDepartment of Urology, Tokyo Women's Medical University Medical Center East, Arakawa, Japan.
Yudai IshiyamaDepartment of Urology, Tokyo Women's Medical University Medical Center East, Arakawa, Japan.
Hidekazu TachibanaDepartment of Urology, Tokyo Women's Medical University Medical Center East, Arakawa, Japan.
Daisuke TokiDepartment of Urology, Tokyo Women's Medical University Medical Center East, Arakawa, Japan.
Kaori YamashitaDepartment of Urology, Tokyo Women's Medical University Medical Center East, Arakawa, Japan.
Hirohito KobayashiDepartment of Urology, Tokyo Women's Medical University Medical Center East, Arakawa, Japan.
Hironori FukudaDepartment of Urology, Tokyo Women's Medical University, Shinjuku, Japan.
Kazuhiko YoshidaDepartment of Urology, Tokyo Women's Medical University, Shinjuku, Japan.
Toshio TakagiDepartment of Urology, Tokyo Women's Medical University, Shinjuku, Japan.
Junpei IizukaDepartment of Urology, Tokyo Women's Medical University, Shinjuku, Japan.
Hideki IshidaDepartment of Urology, Tokyo Women's Medical University, Shinjuku, Japan.
Tsunenori KondoDepartment of Urology, Tokyo Women's Medical University Medical Center East, Arakawa, Japan; tkondo@twmu.ac.jp.
Kazunari TanabeDepartment of Urology, Tokyo Women's Medical University, Shinjuku, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND/

aimThe relationship between albumin-to-alkaline phosphatase ratio (AAPR) and the outcome of patients with metastatic renal cell carcinoma (mRCC) treated with immune checkpoint inhibitors remains unresolved. We aimed to clarify the prognostic role of AAPR in nivolumab monotherapy for previously treated mRCC. PATIENTS AND

methodsWe retrospectively evaluated 60 patients with mRCC treated with nivolumab after failure of at least one molecular targeted therapy. The patients were stratified into two groups based on the baseline AAPR. The threshold of AAPR was determined using receiver-operating characteristics and Youden index analyses. Overall survival (OS), progression-free survival (PFS), and objective response rate (ORR) of nivolumab therapy were compared between the high and low AAPR groups.

resultsThe threshold of AAPR was set at 0.3, and 20 patients (33%) were assigned to the low AAPR group. The median OS and PFS were significantly lower in the low AAPR group than those in the high group (OS: 8.3 months vs. not reached, p<0.0001; PFS: 2.9 vs. 10.4 months, p=0.0006). Moreover, ORR was significantly lower in the low AAPR group than in the high group (16% vs. 45%, p=0.0397). Multivariate analyses further showed that AAPR was an independent factor for OS [HR=0.27 (95% CI=0.09-0.77), p=0.0151] but not for PFS (p=0.174).

conclusionBaseline AAPR was significantly associated with outcome in patients with mRCC receiving nivolumab monotherapy and may, therefore, constitute an effective prognostic factor for nivolumab treatment.

Indexed as

Carcinoma, Renal CellKidney NeoplasmsAlbuminsAlkaline PhosphataseHumansNivolumabPrognosisRetrospective StudiesAlbuminsAlkaline PhosphataseNivolumabALPbiomarkersimmune checkpoint inhibitorKidney cancerPD-1

Identifiers

PMID34410978
PMCPMC8408722

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.